EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 34 / No 4 (Avril 2018) Med Sci (Paris), 34 4 (2018) 296-299 References
Free Access
Issue
Med Sci (Paris)
Volume 34, Number 4, Avril 2018
Page(s) 296 - 299
Section Le Magazine
DOI https://doi.org/10.1051/medsci/20183404006
Published online 16 April 2018
  1. Barbotin AL, Giacobini P, Prévot V. Le microbiote intestinal : clé de voûte entre l’obésité maternelle et les troubles de la socialisation chez la descendance. Med Sci (Paris) 2016; 32 : 930-2. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  2. Burcelin R, Simon Nicolas S, Blasco-Baque V. Microbiotes et maladies métaboliques : de nouveaux concepts pour de nouvelles stratégies thérapeutiques. Med Sci (Paris) 2016; 32 : 952-60. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Teixeira-Clerc F, Julien B, Grenard P et al. Les antagonists du récepteur CB1 des cannabinoïdes : une nouvelle approche pour le traitement de la fibrose hépatique. Med Sci (Paris) 2006; 22 : 683-85. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  4. Silvestri C, Di Marzo V. The endocannbinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 2013; 17 : 475-90. [CrossRef] [PubMed] [Google Scholar]
  5. Sberna AL, Degrace P, Vergès B. Système endocannabinoïde : effets sur le métabolisme glucidique mais aussi lipidique. Med Mal Metab 2016; 10 : 407-14. [Google Scholar]
  6. Christensen R, Kristensen PK, Bartels EM et al. Efficacy and safety of the weigth-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370 : 1706-13. [CrossRef] [PubMed] [Google Scholar]
  7. Tam J, Vemuri VK, Liu J, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010; 120 : 2953-66. [CrossRef] [PubMed] [Google Scholar]
  8. Tam J, Cinar R, Liu J, et al. Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance. Cell Metab 2012; 16 : 167-79. [CrossRef] [PubMed] [Google Scholar]
  9. Silvestri C, Di Marzo V. Second generation CB, receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Expert Opin Investig Drugs 2012; 21 : 1309-22. [CrossRef] [PubMed] [Google Scholar]
  10. Ruiz de Azua I, Mancini G, Srivastava RK et al. Adipocyte cannabinoid receptor CB1 regulates energy homeostasis and alternatively activated macrophages. J Clin Invest 2017; 127 : 4148-62. [CrossRef] [PubMed] [Google Scholar]
  11. Carrière A, Jeanson Y, Cousin B et al. Le recrutement et l’activation d’adipocytes bruns et/ou BRITE : une perspective réelle pour le traitement des maladies métaboliques ? Med Sci (Paris) 2013; 29 : 729-35. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  12. Bowles NP, Karatsoreos IN, Li X, et al. Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008; 118 : 3160-9. [CrossRef] [PubMed] [Google Scholar]
  13. Osei-Hyiaman D, Liu J, Zhou L, et al. A peripheral endocannabinoid mechanism contributes to glucocorticoid-mediated metabolic syndrome. Proc Natl Acad Sci USA 2015; 112 : 285-90. [CrossRef] [Google Scholar]
  14. Meye FJ, Trezza V, Vanderschuren LJ et al. Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity. Mol Psychiatry 2013; 18 : 1294-301. [CrossRef] [PubMed] [Google Scholar]
  15. Heimann AS, Gomes I, Dale CS, et al. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc Natl Acad Sci USA 2007; 104 : 20588-93. [CrossRef] [Google Scholar]
  16. Dodd GT, Mancini G, Lutz B, et al. The peptide hemopressin acts through CB1 cannabinoid receptors to reduce food intake in rats and mice. J Neurosci 2010; 30 : 7369-76. [CrossRef] [PubMed] [Google Scholar]
  17. Simon V, Cota D. Endocannabinoids and metabolism: past, present and future. Eur J Endocrinol 2017; 176 : R309-24. [Google Scholar]
  18. Pintus S, Murru E, Carta G, et al. Sheep cheese naturally enriched in alpha-linolenic, conjugated linoleic and vaccenic acids improves the lipid profile and reduces anandamide in the plasma of hypercholesterolaemic subjects. Br J Nutr 2013; 109 : 1453-62. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.